Study of effectiveness of antiviral drugs (umifenovir, triazavirin) against acute respiratory viral infections

Abstract

Aim. Comparative study of clinical efficacy and safety of antiviral drug triazavirin and umifenovir in the treatment of patients with acute respiratory viral infections and influenza.

Methods. The study included 100 patients aged 18 to 65 years diagnosed with moderate acute respiratory viral infection. Group 1 included 34 patients receiving umifenovir 200 mg 4 times a day for 5 days, and comparison group included 32 patients who received triazavirin 1 capsule (250 mg) 3 times a day for 5 days. Group 3 (control group) included 34 patients not treated with antiviral therapy. Efficacy and safety of the studied antiviral drugs were evaluated based on clinical symptoms in the disease course and were confirmed by adaptive reactions of the organism.

Results. Among patients receiving triazavirin, recovery time and fever, headache and catarrhal syndrome resolution time were less than among patients who received umifenovir. On triazavirin treatment with favorable tolerability, symptomatic medications (antipyretics) were discontinued, and the duration of their use was less, than in patients receiving umifenovir. Evaluation of clinical efficacy of umifenovir and triazavirin for the treatment of acute respiratory viral infections and influenza demonstrated that the drugs effectively reverse the main symptoms of the disease (p <0.05), reduce complications incidence (18.1±2.1% vs. 55.9±3.2%, p <0.05) and contribute to the stabilization of adaptive reactions of the organism in contrast to the results of patients not receiving etiotropic therapy (6.9±2.9% vs. 12.8±2.7, p <0.05). During the use of umifenovir by day 4 and during the use of triazavirin by day 3 intoxication and catarrhal syndromes had been reversed, while in case of the absence of antiviral therapy, 55.8% of patients had continuing intoxication and catarrhal symptoms.

Conclusion. The results of the study allow defining umifenovir and triazavirin as the first line of defense against acute respiratory viral infections with good efficacy and tolerability of the drugs.

Keywords

acute respiratory viral infection / influenza / influenza antiviral therapy / umifenovir / triazavirin

References

[1] Sologub T.V., Tsybalova L.M., Tokin I.I., Tsvetkov V.V. Gripp v praktike klinitsista, epidemiologa i virusologa. (Influenza in the practice of a clinician, epidemiologist and virologist.) Moscow: MIA. 2017; 272 p. (In Russ.)

[2] Сологуб Т.В., Цыбалова Л.М., Токин И.И., Цветков В.В. Грипп в практике клинициста, эпидемиолога и вирусолога. М.: МИА. 2017; 272 с.

[3] Sitnikov I.G., Eganyan G.A., Groppa L.G. et al. Treatment of flu and ARVI in routine clinical practice: outcomes of intermediate analysis of non-intervention open prospective observatory research. Lechaschiy vrach. 2015; (3): 95–99. (In Russ.)

[4] Ситников И.Г., Еганян Г.А., Гроппа Л.Г. и др. Лечение ОРВИ и гриппа в рутинной клинической практике: результаты промежуточного анализа неинтервенционного открытого проспективного наблюдательного исследования. Леч. врач. 2015; (3): 95-99.

[5] Sergeeva I.V., Kamzalakova N.I., Tikhonova E.P. et al. Pathogenesis acute respiratory viral infections and influenza. Prakticheskaya meditsina. 2012; 61 (6): 47–50. (In Russ.)

[6] Сергеева И.В., Камзалакова Н.И., Тихонова Е.П. и др. Патогенез острых респираторных вирусных инфекций и гриппа. Практич. мед. 2012; 61 (6): 47-50.

[7] Leneva I.A., Fedyakina I.T., Gus'kova T.A. et al. Sensitivity of different influenza virus strains to Arbidol. Study of the effect of Arbidol on influenza virus A reproduction in combination with different antiviral drugs. Terapevticheskiy arkhiv. 2005; (8): 84–88. (In Russ.)

[8] Ленева И.А., Федякина И.Т., Гуськова Т.А. и др. Чувствительность различных штаммов вируса гриппа к Арбидолу. Изучение эффекта Арбидола на репродукцию вируса гриппа А в комбинации с различными противовирусными препаратами. Терап. архив. 2005; (8): 84-88.

[9] Triazavirin — protivovirusnyy preparat novogo pokoleniya. (Triazavirin — an antiviral drug of the new generation.) Ed. by O.N. Chupakhin, O.I. Kiselev. Yekaterinburg: Institut organicheskogo sinteza im. I.Ya. Postovskogo. 2016; 254 p. (In Russ.)

[10] Триазавирин - противовирусный препарат нового поколения. Под ред. О.Н. Чупахина, О.И. Киселёва. Екатеринбург: Институт органического синтеза им. И.Я. Постовского. 2016; 254 с.

[11] Sologub T.V., Tokin I.I., Midikari A.S., Tsvetkov V.V. A comparative efficacy and safety of using antiviral drugs in therapy of patients with influenza. Infektsionnye bolezni. 2017; 15 (3): 25–32. (In Russ.)

[12] Сологуб Т.В., Токин И.И., Мидикари А.С., Цветков В.В. Сравнительная эффективность и безопасность применения противовирусных препаратов в терапии больных гриппом. Инфекц. болезни. 2017; 15 (3): 25-32. DOI: 10.20953/1729-9225-2017-3-25-32.

[13] Deeva E.G., Rusinov V.L., Charushin V.N. et al. An antiviral medication Triazavirin: from screening to clinical approbation. Razrabotka i registratsiya lekarstvennykh sredstv. 2014; 7 (7): 144–151. (In Russ.)

[14] Деева Э.Г., Русинов В.Л., Чарушин В.Н. и др. Противовирусный препарат Триазавирин: от скрининга до клинической апробации. Разработка и регистрация лекарственных средств. 2014; 7 (7): 144-151.

[15] Davydova L.A. Teoriya statistiki v voprosakh i otvetakh. (Theory of statistics in the questions and answers.) Moscow: TK Velbi, izd-vo «Prospekt». 2006; 160 p. (In Russ.)

[16] Давыдова Л.А. Теория статистики в вопросах и ответах. М.: ТК Велби, изд-во «Проспект». 2006; 160 с.

[17] Garkavi L.Kh., Kvakina E.B., Ukolova M.A. Adaptatsionnye reaktsii i rezistentnost' organizma. (Adaptive reactions and organsim's resistance.) Rostov-on-Don: Izdatel'stvo Rostov. universiteta. 1977; 120 p. (In Russ.)

[18] Гаркави Л.Х., Квакина Е.Б., Уколова М.А. Адаптационные реакции и резистентность организма. Ростов-на-Дону: Изд-во Ростов. ун-та. 1977; 120 с.

[19] Velikaya O.V., Provotorov V.M., Martyshova O.S., Zhukova M.S. Determination of severity of chronic obstructive pulmonary disease exacerbation for the choice of optimal treatment of patients. Sistemnyy analiz i upravlenie v biomeditsinskikh sistemakh. 2011; 10 (3): 531–535. (In Russ.)

[20] Великая О.В., Провоторов В.М., Мартышова О.С., Жукова М.С. Определение степени тяжести обострения хронической обструктивной болезни лёгких для выбора оптимального лечения пациентов. Системный анализ и управление в биомед. системах. 2011; 10 (3): 531-535.

[21] Marchuk G.I. Matematicheskie modeli v immunologii. Vychislitel'nye metody i eksperimenty. (Mathematical models in immunology. Computational models and experiments.) Moscow: Nauka. 1991; 299 p. (In Russ.)

[22] Марчук Г.И. Математические модели в иммунологии. Вычислительные методы и эксперименты. М.: Наука. 1991; 299 с.

[23] Raznatovskaya E.N. Integrated indices of endogenious intoxication in patients with drug-resistant pulmonary tuberculosis. Prakticheskaya meditsina. 2012; 2 (9): 119–120. (In Russ.)

[24] Разнатовская Е.Н. Интегральные индексы эндогенной интоксикации у больных химиорезистентным туберкулёзом лёгких. Практич. мед. 2012; 2 (9): 119-120.

RIGHTS & PERMISSIONS

Tikhonova E.P., Kuz'mina T.Y., Andronova N.V., Tyushevskaya O.A., Elistratova T.A., Kuz'min A.E.